Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

EULAR: Enbrel (Etanercept) Effective In Patients With Psoriatic Arthritis And Psoriasis By Thomas Buckingham PRAGUE, CZECH REPUBLIC -- June 14, 2001 -- Results were presented today at the European League Against Rheumatism (EULAR) meeting showing the efficacy of Enbrel (etanercept) for psoriasis and psoriatic arthritis. Dr. P.J. Mease, Clinical Rheumatology, a rheumatologist with Minor and James Medical, in Seattle, Washington, said psoriasis affects 2 to 3 percent of the population and of these 7 to 25 percent have psoriatic arthritis (PsA). Results from a previously published 12-week, double-blind, placebo-controlled study of 60 patients with PsA and psoriasis (Mease PJ. Lancet 2000;356:385-90) showed that Enbrel was well tolerated and provided clinically significant benefit to patients with PsA and psoriasis. The purpose of the present study was to examine the drug’s effect in these same patients in a longer-term open-label study. Fifty-eight patients received open-label Enbrel in a 24-week extension study and were evaluated according to PsA response criteria (PsARC) and American College of Rheumatology criteria. Thirty-seven patients with psoriasis were evaluated using the Psoriasis Area and Severity Index (PASI). The original Enbrel patients sustained their improvement in both PsA and psoriasis and the original placebo patients improved after they began receiving Enbrel. Most (81 percent) patients achieved the PsARC at 36 weeks and 55 percent achieved ACR 50 response. The patients with psoriasis (n = 37) achieved median improvements of 62 percent in the PASI. Twenty-eight patients were taking concomitant methotrexate (MTX) at baseline. Many (43 percent) have decreased their methotrexate dose and 25 percent have discontinued methotrexate. Eighteen patients were on corticosteroids at baseline. Most (67 percent) have decreased their dose and 44 percent have discontinued steroids. Enbrel was found to be well tolerated, with no serious adverse events or infections and no increase in adverse events with longer exposure, Dr. Mease said. Enbrel was safe and effective in reducing the signs and symptoms of PsA and psoriasis during 36 weeks of treatment, he concluded. SOURCE: PeerView Press E-mail this page to a friend or colleague! To print, use this version